The launch of the group’s lead cough cold product, TuzistraTM XR, in the US following FDA approval in April is a key development for Vernalis. We re-iterate our Buy recommendation and 93p target price.
08 Sep 2015
TuzistraTM XR launched in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
TuzistraTM XR launched in the US
The launch of the group’s lead cough cold product, TuzistraTM XR, in the US following FDA approval in April is a key development for Vernalis. We re-iterate our Buy recommendation and 93p target price.